Sustained Glucocorticoid Tapering in the Phase 3 Trials of Anifrolumab: A post hoc Analysis of the TULIP-1 and TULIP-2 Trials

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/keac491

Pooled analysis of the TULIP trials demonstrates that sustained glucocorticoid (GC) tapering is associated with several clinical benefits in patients with moderate-to-severe SLE.

Despite their association with a significant burden of toxicity, GCs are still used in around 80% of patients with SLE. Consequently, GC sparing is currently a key priority for SLE management. With this in mind, Bruce, et al. evaluated the effects of sustained GC tapering in patients with SLE, using data from the anifrolumab TULIP-1 and TULIP-2 trials.